Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (Nasdaq: TDAC) is a healthcare and life sciences-focused special purpose acquisition company that completed its IPO in 2020. The company targets opportunities at the intersection of translational medicine and commercial healthcare, seeking targets where laboratory-stage innovation can be advanced toward clinical and market application. A Form 425 filing submitted on August 3, 2026 indicates TDAC is in an active business combination process, as this disclosure type is required for communications made in connection with a proposed merger or acquisition. For full sponsor details, deal timeline, and complete filing history on TDAC, sign up for access at SpacDesk.